Product correctly added to cart.

No image

CAS 1024033-43-9: AZD4017

Description:AZD4017, with the CAS number 1024033-43-9, is a chemical compound that has been investigated primarily for its potential therapeutic applications. It is classified as a selective antagonist of the neurokinin-1 (NK1) receptor, which is involved in various physiological processes, including pain perception, stress response, and the regulation of mood. The compound's structure typically features a core that allows for specific interactions with the NK1 receptor, thereby inhibiting its activity. This mechanism of action positions AZD4017 as a candidate for treating conditions such as anxiety, depression, and other neuropsychiatric disorders. In terms of physical properties, AZD4017 may exhibit moderate solubility in organic solvents and limited solubility in water, which is common for many small organic molecules. Its pharmacokinetic profile, including absorption, distribution, metabolism, and excretion, is crucial for determining its efficacy and safety in clinical settings. Ongoing research continues to explore its full potential and therapeutic applications.

Sort by


See more categories

This search does not contain any category.

Found 4 products.

discount label

3-Piperidineacetic acid, 1-[5-[(cyclohexylamino)carbonyl]-6-(propylthio)-2-pyridinyl]-, (3S)-

CAS:1024033-43-9

Ref: IN-DA0007CW

1mg195.00 €
5mg330.00 €
10mg549.00 €
25mgTo inquire
50mgTo inquire
100mgTo inquire
Estimated delivery in United States, on Tuesday 4 Mar 2025
discount label

Ref: 54-OR305432

Undefined sizeTo inquire
Estimated delivery in United States, on Monday 3 Mar 2025
discount label

AZD 4017

CAS:1024033-43-9

Ref: 3D-BA166507

10mg348.00 €
25mg521.00 €
Estimated delivery in United States, on Tuesday 15 Apr 2025
discount label

AZD 4017

CAS:1024033-43-9

Ref: TM-T14388

1mg73.00 €
5mg160.00 €
10mg274.00 €
25mg550.00 €
50mg792.00 €
100mg1,093.00 €
1mL*10mM (DMSO)170.00 €
Estimated delivery in United States, on Tuesday 6 May 2025
Welcome to CymitQuimica!We use cookies to enhance your visit. We do not include advertising.

Please see our Cookies Policy for more details or adjust your preferences in "Settings".